News & Updates

Professor Jean-Jacques Kiladjian, Professor of Clinical Pharmacology, Consultant Haematologist, and head of the Clinical Investigation Centre of Hôpital Saint-Louis & Université Paris Cité in Paris, France, discusses the drawbacks of conventional therapy for PV, and how ropeginterferon alfa-2b may support a shift in treatment.

MIMS Oncology explores the current landscape of polycythaemia vera management in Singapore and the role of the newly launched ropeginterferon alfa-2b in improving patient outcomes. During an interview, Dr Dawn Mya, a leading haematologist practicing at Parkway Cancer Centre, Singapore, provides expert insights into the therapeutic potential of this novel treatment.

Evidence from a large population-based study shows no consistent association between an increased risk of cancer and exposure to antihypertensive drugs.

Women with early-stage breast cancer (BC) entering randomized controlled trials (RCTs) after the 2000s have reduced rates of distant recurrence vs the 1990s, a patient-level pooled analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has shown. 

The novel, small-molecule, orally administered third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) olverembatinib is well-tolerated and shows promising antitumour activity in patients with heavily pretreated chronic-phase chronic myeloid leukaemia (CML), according to the results of a phase 1B study.

A cohort study conducted by researchers from the University of Hong Kong (HKU) reports a complete response (CR) rate of 46.0 percent among patients with locally advanced, unresectable hepatocellular carcinoma (HCC) who were treated with locoregional therapy (LRT) plus immunotherapy (IO) and a 3-year overall survival (OS) rate of 75.5 percent among patients with CR.

The international, multicentre, randomized phase III GCIG INTERLACE trial reports significantly higher 5-year progression-free survival (PFS) and overall survival (OS) rates with induction chemotherapy followed by chemoradiotherapy (CRT) vs CRT alone in patients with locally advanced cervical cancer.